3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
72
Neoplasms
64
Prostatic Neoplasms
45
Colorectal Neoplasms
42
Lung Neoplasms
38
Carcinoma, Non-Small-Cell Lung
26
Pancreatic Neoplasms
21
Neoplasm Metastasis
20
Hematologic Neoplasms
20
Head and Neck Neoplasms
20
Urinary Bladder Neoplasms
15
Ovarian Neoplasms
14
Multiple Myeloma
11
Motor Activity
11
Leukemia, Myeloid, Acute
11
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Uterine Cervical Neoplasms
9
Triple Negative Breast Neoplasms
9
Glioblastoma
9
Colonic Neoplasms
9
Hematopoietic and Lymphatic System Neoplasm
8
Glioma
8
Gastrointestinal Neoplasms
8
Carcinoma, Renal Cell
8
COVID-19
8
Anxiety Disorders
8
Anatomic Stage I Breast Cancer AJCC v8
8
Rectal Neoplasms
7
Melanoma
7
Interventions
Temozolomide
11
Cyclophosphamide
11
Radiotherapy
7
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Cisplatin
6
Vincristine
5
Etoposide
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
sargramostim
3
Thiotepa
3
Melphalan
3
Carmustine
3
Automobiles
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
gallium Ga 68 dotatate
2
fludarabine
2
dactolisib
2
aldesleukin
2
Thalidomide
2
TH 302
2
Paclitaxel
2
Irinotecan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Everolimus
2
Donepezil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroectodermal Tumors, Primitive
×
Standard of Care
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled